Skip to Content

Five Prime Therapeutics, Inc.

Merger

  • Date:
  • 3/4/2021
  • Company Name:
  • Five Prime Therapeutics, Inc.
  • Stock Symbol:
  • FPRX
  • Company Name - Buyer:
  • Amgen Inc.
  • Stock Symbol - Buyer:
  • AMGN
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 3/4/2021

Case Finder

Locate any case using the tools below.

NEW YORK, March 4, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen Inc. (NASDAQ: AMGN).

On March 4, 2021, Five Prime announced that it had signed an agreement to be acquired by Amgen for approximately $1.9 billion.  Pursuant to the merger agreement, Five Prime stockholders will receive $38 in cash for each share of Five Prime common stock owned.  The deal is scheduled to close in the second quarter of 2021.

Bragar Eagel & Squire is concerned that Five Prime’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Five Prime’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Five Prime Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: